Sumagen Canada Inc. is a solely owned subsidiary of Sumagen Co., Ltd.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd. Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team. In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development. The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.
Korean company CUROCOM founded 1997.
ReplyDelete